- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03384784
Effect of Galantamine on Inflammation and Cognition (CHI)
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Eligible subjects will be males and females:
- At least 30 years old
- Diagnosed with HIV-1 infection
- On stable ART regimens (no changes to treatment within 4 weeks of Intake visit)
- Viral load of less than or equal to 200 copies/mL
- Current cluster of differentiation (CD4) counts greater than 200
If current or past diagnosis of bipolar disorder, eligible if:
- No psychotic features
- Montgomery-Asberg Depression Rating Scale (MADRS): total score less than 8 (past 4 weeks), suicidal item score less than 1 (past 4 weeks)
- Young Mania Rating Scale (Y-MRS): total score less than 8 (past 4 weeks), irritability, speech content, disruptive or aggressive behavior items score less than 3 (past 4 weeks)
- No psychiatric hospitalization or Emergency Room visits for psychiatric issues in the past 6 months
- No aggressive or violent acts or behavior in the past 6 months
- Able to communicate in English and provide written informed consent
- Will be residing in the geographic area for at least 7 months
- Not currently trying to quit smoking
Smoking Status
- Smokers (HIV+S) will report at least 5 instances of smoking per day, on average for the past year and provide a breath carbon monoxide (CO) sample greater than 5 ppm at Intake and at the beginning of each treatment period
- Non-smokers (HIV+NS) will report smoking fewer than 100 cigarettes in their lifetime, or less than 5 pack years of smoking and no cigarettes in the last year. They will self-report no current use of any tobacco or nicotine product and will provide a CO sample of less than 3 ppm at Intake and at the beginning of each treatment period. If CO sample does not reflect self-report, the PI will be consulted to determine eligibility.
Exclusion Criteria:
Subjects who present with and/or self-report the following criteria will not be eligible to participate in the study.
Smoking Behavior
- Current enrollment or plans to enroll in another smoking cessation program in the next 7 months.
- Regular (daily) use of electronic cigarettes, chewing tobacco, snuff, snus, cigars, cigarillos, or pipes.
- Current use or plans to use nicotine substitutes (gum, patch, lozenge, e-cigarette) or smoking cessation treatments in the next 7 months.
Alcohol/Drug Use
- Current untreated and unstable diagnosis of substance abuse or dependence (if past use and if receiving treatment and stable for at least 30 days, eligible)
- Positive urine drug screen for cocaine, methamphetamines, phencyclidine (PCP), barbiturates, ecstasy (MDMA), at Intake or Lab visits. Those who screen positive for amphetamines, benzodiazepines, methadone, oxycodone, and/or opiates (low level cut-off 300 ng/mL) and who are prescribed these medications will be reviewed on a case-by-case basis by the study physician and PIs (see Measures and Table 1 for details). Participants believed to have a false-positive result on the drug screen may continue in the study, with investigator approval.
Medical/Psychiatric Conditions
- Women who are pregnant, planning a pregnancy or lactating
- Current diagnosis of unstable and untreated major depression (if stable for at least 30 days, eligible)
- Current or past diagnosis of psychotic disorder
- Cancer diagnosis within the past 6 months (except basal cell carcinoma)
- Major heart disease or stroke within the past 6 months
- Uncontrolled hypertension (systolic blood pressure greater than 160 or diastolic blood pressure greater than 100).
Medical conditions contraindicated for use with galantamine:
- Diagnosis of Alzheimer's disease or dementia
- Epilepsy or other seizure disorder
- Bladder outflow obstruction
- Active HCV co-infection (if cured, requires study physician approval)
- Liver function tests more than 20% outside of the normal range; Gamma-glutamyl transpeptidase (GGT) values more than 20% outside of the normal range. If Albumin/Globulin ratios are 20% outside of normal range the abnormal value will be evaluated for clinical significance by the Study Physician and eligibility will determined on a case-by-case basis.
- Renal disease or renal dysfunction (e.g., serum creatinine levels greater than 1.5 X upper limit of normal). Those with moderate hepatic impairment or creatinine clearance 9 to 59 mL/min shall not exceed the 16 mg/day dose.
- Peptic ulcer disease (requires study physician approval)
Suicide risk as indicated by at least one of the following on the Columbia Suicide Severity Rating Scale (the PI and/or study psychologist will be consulted to assess safety and determine eligibility in cases close to the eligibility cutoffs):
- Current suicidal ideation (within 30 days of enrollment)
- Two or more lifetime suicide attempts or episodes of suicidal behavior
- Any suicide attempt or suicidal behavior within 2 years of enrollment
Medication
Current use or discontinuation within the last 14 days of:
- Quit smoking medications including varenicline (Chantix), bupropion (Wellbutrin)
- Anti-psychotic medications (e.g., Zyprexa, Clozaril, Seroquel, Risperdal). If used to treat psychotic symptoms. Other uses may be eligible pending physician approval).
- Systemic Steroids (e.g., Prednisone).
- Alzheimer's disease medications (e.g., Acetylcholinesterase inhibitors (ACIs), Aricept/donepezil, Exelon/rivastigmine, Tacrine, or memantine)
- Irritable bowel syndrome medication (e.g., Dicyclomine/Bentyl)
- Heart medications (e.g., quinidine).
- Muscle relaxants (e.g., Anectine/succinylcholine)
- Anti-seizure medications (e.g. Ativan, Banzel, Carbatrol, Dilantin, Lamictal, Gabitril, Lyrica, Neurontin, Tegretol, Topomax) if used to treat a seizure disorder or epilepsy. Other uses may be eligible.
- Urinary retention medications (e.g., Duvoid/bethanechol, Proscar/finasteride, Avodart/dutasteride, Dibenzyline/ phenoxybenzamine, Regitine/phentolamine)
Daily use of:
- Opiate-containing medications for chronic pain (Duragesic/fentanyl patches, Percocet, Oxycontin). Smokers who report taking opiate-containing medications on an "as-needed" basis will be instructed to refrain from use until their study participation is over and that they will be tested to ensure they have complied with this requirement.
- Chronic obstructive pulmonary disease (COPD) medication (e.g., Atrovent/Ipratropium Bromide)
- Known allergy to study medication.
Subjects will be instructed to refrain from using any study prohibited drugs/medications (both recreational and prescription) throughout their participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Galantamine
This study follows the FDA-recommended dosing regimen for galantamine extended release (GAL ER): 4 weeks at 8 mg (once a day), 4 weeks at 16 mg (once a day), and 4 weeks at 24 mg (once a day). The University of Pennsylvania Investigational Drug Service (IDS) will oversee the randomization of all study medication, purchase study medication, manufacture matched placebo, encapsulate and package them in blister packs to maintain double-blind procedures. |
The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER.
The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d.
dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg.
Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
Other Names:
|
Placebo Comparator: Placebo
12-week placebo-controlled medication period Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at the University of Pennsylvania. Both active medication and placebo will look identical. The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take galantamine during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by galantamine during the second medication period. |
Matched placebo will be made in-house using lactulose filler in gel capsules.
Participants will be instructed to take one pills every morning for 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Cognition
Time Frame: Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)
|
Cognitive function will be assessed 8 times throughout study participation at Lab Visits and Mid-treatment Visits.
Participants will complete measures of executive function, verbal learning and memory and response inhibition.
The primary outcome is the change from baseline cognitive function after 12 weeks of treatment.
Because this is a within-subject crossover study, change in cognition will be measured during each treatment arm.
|
Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)
|
Change in Inflammation
Time Frame: Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)
|
Cellular markers of immune activation will be measured in whole blood and soluble markers of immune activation will be measured in plasma at Lab Visits.
The primary outcome is the change in monocyte and T cell surface activation and soluble markers after 12 weeks of treatment.
Because this is a within-subject crossover study, changes in cellular markers will be measured during each treatment arm.
|
Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monocyte Transcriptomics
Time Frame: Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)
|
Monocytes will be isolated from blood samples and analyzed for differences in monocyte expression between smoking and non-smoking groups and between treatment arms.
Gene expression patterns will also be correlated with soluble and cell surface markers of inflammation.
|
Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rebecca L Ashare, PhD, University of Pennsylvania
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Neurocognitive Disorders
- Dementia
- HIV Infections
- Inflammation
- AIDS Dementia Complex
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Parasympathomimetics
- Galantamine
Other Study ID Numbers
- 828125
- R01DA044906 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The final dataset will include demographic and behavioral assessments and laboratory data bio-specimens. Because the dataset will contain personal health information, identifying information will be collected. Even though the final dataset will be stripped of identifiers prior to release for sharing, investigators will do the following to reduce the possibility confidentiality loss. We will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.
Transcriptomic data will be deposited with a public access database such as NCBI's Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/)
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Associated Cognitive Motor Complex
-
University of Alabama at BirminghamNational Institute of Nursing Research (NINR)CompletedCognitive Impairment | Aging | Cognitive Decline | Attention Impaired | Cognitive Deficit in Attention | HIV-Associated Cognitive Motor Complex | Processing, Visual Spatial | Cognitive Disorder in RemissionUnited States
-
Vanderbilt University Medical CenterCompletedCognitive Impairment | Memory Impairment | HIV-1-infection | Aging, Premature | HIV-Associated Cognitive Motor ComplexUnited States
-
National Institute of Mental Health (NIMH)TerminatedHIV Infections | Healthy | AIDS Dementia Complex | AIDS-Related Dementia Complex | HIV-Associated Cognitive Motor Complex | HIV-Dementia | AIDS EncephalopathyUnited States
-
National Institute of Mental Health (NIMH)TerminatedHIV-Associated Cognitive Motor ComplexUnited States
-
Johns Hopkins UniversityTerminatedHIV Dementia | HIV-Associated Cognitive Motor ComplexUnited States
-
National Institutes of Health Clinical Center (CC)CompletedDepression | HIV Infections | HIV-Associated Cognitive Motor ComplexUnited States
-
Holdsworth House Medical PracticeCompletedHIV-1-Associated Cognitive Motor Complex
-
University of HawaiiTobira Therapeutics, Inc.CompletedAIDS Dementia Complex | Human Immunodeficiency Virus | HIV-1-Associated Cognitive Motor ComplexUnited States
-
Johns Hopkins UniversityMakerere UniversityTerminatedHIV Infections | HIV-associated Cognitive ImpairmentUganda
-
School of Health Sciences GenevaSwiss National Science FoundationCompleted
Clinical Trials on Galantamine
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Samsung Medical CenterJanssen Korea, Ltd., KoreaCompleted
-
Ludwig-Maximilians - University of MunichUnknownAlzheimer's DiseaseGermany
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH); Massachusetts General HospitalCompletedBipolar DisorderUnited States
-
The University of Texas Health Science Center,...Completed
-
Janssen Pharmaceutical K.K.CompletedAlzheimer's DiseaseJapan
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedAlzheimer Disease
-
Actavis Inc.Completed
-
Actavis Inc.Completed